Case Study 2 — Cadaver Growth Hormone

What happens when a hormone can only be obtained from human tissue

Type: Real, public, historical · Tier 1 facts · Relevance: §3.2, §3.3 · Bridges to Chapters 14 and 32

Background: a hormone you could not make

By the late 1950s, growth hormone's role was understood well enough to try replacing it. Children with severe growth hormone deficiency did not grow, and it was clear that supplying the hormone should help.

There was one obstacle, and it was absolute. Growth hormone is species-specific. Unlike insulin, where pig and cow versions are similar enough to human insulin to work in people — which is how diabetes was treated for sixty years — growth hormone from animals does not work in humans. The molecule differs too much.

So the only source of human growth hormone was human pituitary glands. And the only way to obtain those was from cadavers.

This is what was done. From roughly 1958 onward, national programs in several countries — the United States, the United Kingdom, France, Australia, and others — collected pituitary glands at autopsy, extracted growth hormone, and distributed it to children with severe deficiency.

The arithmetic was brutal. A single pituitary yields a very small quantity of hormone. Treating one child for one year required glands from a large number of donors. Supply was the permanent binding constraint, and programs had to ration: only the most severely affected children were treated, and often at doses below what would have been ideal, for as long as supply permitted.

The treatment worked. Children who would not have grown, grew. For a quarter of a century, this was a genuine and hard-won medical success, run largely by national health services and academic consortia rather than by industry.

What went wrong

In 1985, a young adult in the United States who had received cadaver-derived growth hormone as a child died of Creutzfeldt-Jakob disease — a rare, invariably fatal, rapidly progressive neurodegenerative disease.

Then another case. Then cases in other countries.

Creutzfeldt-Jakob disease is caused by prions — misfolded proteins that induce normal proteins to misfold in the same way, propagating through nervous tissue. Prions are not living organisms. They have no genetic material. And critically, they are extraordinarily resistant to the sterilization methods that kill bacteria and viruses — heat, radiation, standard disinfectants. Nothing in the purification process used for cadaver growth hormone had been designed to remove them, because when those processes were designed, prions were not understood to exist.

The incubation period is very long — often decades. Which meant that by the time the first cases appeared, thousands of children had already been treated, and there was no way to know who had received contaminated material.

Distribution of cadaver-derived growth hormone was halted in the United States and other countries in 1985. Over the following decades, cases continued to appear in recipients around the world. The affected individuals were, in the main, people who had received the treatment as children and developed the disease as adults.

What replaced it

The timing here is one of the more consequential coincidences in pharmaceutical history.

Recombinant DNA technology arrived at almost exactly the moment it was needed. Recombinant human insulin had been approved in 1982 — the first recombinant drug — establishing that a human protein could be produced by engineered bacteria at scale. Recombinant human growth hormone followed, becoming available in the mid-1980s, essentially as the cadaver programs were shutting down.

The consequences were total:

• Supply became effectively unlimited. No more rationing by donor availability.
• The prion route was eliminated. Bacteria do not carry human prions. The contamination pathway did not merely become less likely; it ceased to exist.
• Purity became controllable. A defined manufacturing process replaced extraction from heterogeneous human tissue.
• And the indication expanded — dramatically. With supply no longer the constraint, growth hormone moved beyond severe deficiency into other conditions, and eventually into the off-label and anti-aging use that Chapter 14 examines.

That last consequence is worth sitting with. The anti-aging growth hormone industry exists because a prion tragedy forced the development of a manufacturing method that removed the supply constraint. Nobody planned that chain of causation, and it is not a criticism of anyone in it.

🩺 Safety and Risk — what this case teaches about "natural"

Cadaver-derived growth hormone was, in the most literal possible sense, natural. It was human growth hormone, produced by a human pituitary, unmodified. No synthesis, no engineering, no unnatural residues.

The recombinant replacement is produced by genetically engineered bacteria in a fermentation tank.

The natural one transmitted a fatal disease. The engineered one does not.

This is not an argument that engineered is always safer. It is an argument that the natural/ synthetic axis does not predict safety at all — that it is orthogonal to the question. What predicts safety is: what is actually in the preparation, how it was made, what could contaminate it, and whether anyone has checked.

Chapter 1 made this point with botulinum toxin and ricin. This case makes it with a treatment that was given to children by national health services, in good faith, using the best available method, for twenty-seven years.

Hold this alongside Chapter 19. The gray-market peptide market's central risk is not that its compounds are synthetic. It is that nobody knows what is in the vial, and the history of medicine contains more than one episode where that turned out to matter in a way nobody anticipated — including in preparations that were entirely natural.

Why this belongs in Chapter 3

It shows why the axis structure matters practically. Growth hormone is a pituitary hormone — tier 2. There is no way to obtain it from a target gland, no animal substitute, and no small-molecule mimic. The only options are: extract it from human pituitaries, make it recombinantly, or act at a different tier of the axis.

That last option is the origin of the secretagogue idea. If you cannot easily obtain growth hormone, act upstream — stimulate the pituitary to release its own. GHRH and its analogs come directly out of this line of reasoning, and while the supply problem that motivated it has been solved, the compounds and the argument have persisted into a very different context. Chapter 15.

And it prefigures Chapter 32's manufacturing chapter. The question of how a peptide is made is not a technical footnote. It determined who could be treated, how many, at what dose, and — as it turned out — whether they survived.

Discussion questions

1. Cadaver-derived growth hormone was the best available treatment, given in good faith, and it transmitted a fatal disease with a decades-long incubation period. Was anyone at fault? What would fault even mean, given that prions were not understood when the purification processes were designed?

2. Supply constraints forced rationing: only the most severely affected children were treated. When recombinant hormone removed the constraint, use expanded far beyond the original indication. Is that expansion a good thing, a bad thing, or both? What determines the answer?

3. The natural product was dangerous and the engineered one is not. Construct the strongest argument you can that "natural" nonetheless carries useful information about safety. Then say why you find it convincing or not.

4. The incubation period was decades. What does that imply about how confident anyone can be about the long-term safety of a compound that has been in use for five years? Apply this to at least one compound you expect to meet in Part III.

5. Recombinant technology arrived essentially as it was needed. How much of medical progress do you think is this kind of timing? Does the answer change how you evaluate a claim that a current problem is "about to be solved"?

6. Bridge forward. Chapter 19 covers gray-market peptides of unverified origin. Using this case, articulate specifically what risk category "unverified origin" belongs to — and why testing a sample for the peptide it claims to contain would not have detected the problem here.